Treatment of refractory germ-cell tumours with single-agent cabazitaxel
Standard
Treatment of refractory germ-cell tumours with single-agent cabazitaxel : a German Testicular Cancer Study Group case series. / Oing, Christoph; Hentrich, Marcus; Lorch, Anja; Gläser, Dietrich; Rumpold, Holger; Ochsenreither, Sebastian; Richter, Stephan; Dieing, Annette; Zschäbitz, Stefanie; Pereira, Ronnie Rodrigues; Bokemeyer, Carsten; Seidel, Christoph.
in: J CANCER RES CLIN, Jahrgang 146, Nr. 2, 02.2020, S. 449-455.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Treatment of refractory germ-cell tumours with single-agent cabazitaxel
T2 - a German Testicular Cancer Study Group case series
AU - Oing, Christoph
AU - Hentrich, Marcus
AU - Lorch, Anja
AU - Gläser, Dietrich
AU - Rumpold, Holger
AU - Ochsenreither, Sebastian
AU - Richter, Stephan
AU - Dieing, Annette
AU - Zschäbitz, Stefanie
AU - Pereira, Ronnie Rodrigues
AU - Bokemeyer, Carsten
AU - Seidel, Christoph
PY - 2020/2
Y1 - 2020/2
N2 - PURPOSE: Outcomes of multiply relapsed, refractory germ-cell tumour (GCT) patients remain poor with an overall survival (OS) of a few months only. Thus, new therapeutic advances are urgently needed. Cabazitaxel has shown preclinical activity in platinum-resistant GCT models. Here, we report the first clinical case series of cabazitaxel treatment for platinum-refractory GCT.METHODS: Data of multiply relapsed GCT patients receiving single-agent cabazitaxel were retrospectively analysed. Endpoints included 12-week progression-free survival (PFS) rate, disease control rate, tumour marker responses, median PFS and OS, and toxicity.RESULTS: Cabazitaxel showed limited activity in 13 heavily pre-treated GCT patients. After a median follow-up of 23 weeks (IQR 29), 69% of patients were deceased. A median of 2 cycles of cabazitaxel (range 1-7) were applied. The 12-week PFS rate was 31%. Median PFS and OS were 7 and 23 weeks, respectively. Two patients achieved objective responses (15%), three patients (23%) achieved a tumour marker decline ≥ 50%, and the disease control rate was 39%. Cabazitaxel was well tolerated. CTCAE° III-IV haemato-toxicity was most common (54%), and dose reductions were scarce (15%).CONCLUSION: In this case series, cabazitaxel showed limited activity in heavily pre-treated GCT patients. Two-phase II studies are underway (NCT02115165, NCT02478502) prospectively assessing cabazitaxel in multiply relapsed GCTs.
AB - PURPOSE: Outcomes of multiply relapsed, refractory germ-cell tumour (GCT) patients remain poor with an overall survival (OS) of a few months only. Thus, new therapeutic advances are urgently needed. Cabazitaxel has shown preclinical activity in platinum-resistant GCT models. Here, we report the first clinical case series of cabazitaxel treatment for platinum-refractory GCT.METHODS: Data of multiply relapsed GCT patients receiving single-agent cabazitaxel were retrospectively analysed. Endpoints included 12-week progression-free survival (PFS) rate, disease control rate, tumour marker responses, median PFS and OS, and toxicity.RESULTS: Cabazitaxel showed limited activity in 13 heavily pre-treated GCT patients. After a median follow-up of 23 weeks (IQR 29), 69% of patients were deceased. A median of 2 cycles of cabazitaxel (range 1-7) were applied. The 12-week PFS rate was 31%. Median PFS and OS were 7 and 23 weeks, respectively. Two patients achieved objective responses (15%), three patients (23%) achieved a tumour marker decline ≥ 50%, and the disease control rate was 39%. Cabazitaxel was well tolerated. CTCAE° III-IV haemato-toxicity was most common (54%), and dose reductions were scarce (15%).CONCLUSION: In this case series, cabazitaxel showed limited activity in heavily pre-treated GCT patients. Two-phase II studies are underway (NCT02115165, NCT02478502) prospectively assessing cabazitaxel in multiply relapsed GCTs.
U2 - 10.1007/s00432-019-03071-2
DO - 10.1007/s00432-019-03071-2
M3 - SCORING: Journal article
C2 - 31838576
VL - 146
SP - 449
EP - 455
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 2
ER -